Published August 4, 2025 | Version v1
Journal article Open

mRNA-BASED THERAPEUTICS BEYOND VACCINES: APPLICATIONS IN ONCOLOGY

Authors/Creators

  • 1. Pharm.D, Saravanagiri8@gmail.com.
  • 2. Pharm.D, azangaier@gmail.com.
  • 3. Pharm.D, adarshsk496@gmail.com.
  • 4. Pharm.D, rijumidnapore@gmail.com.
  • 5. Pharm.D, anirbandebnath304@gmail.com.
  • 6. Pharm.D, Afrahshariff.23@gmail.com.
  • 7. Pharm.D, rroshinee99@gmail.com.
  • 8. Clinical Pharmacologist, Pharm.D, DNHE, DAFE, dr.gopalsuryavanshi@gmail.com.
  • 9. Pharm.D, mehroshpatel1@gmail.com
  • 10. Pharm.D, darshandeshmukh3000@gmail.com

Description

Messenger RNA (mRNA) therapeutics grabbed the world's attention during
the COVID-19 pandemic vaccine development, but the potentials of mRNA
vaccines go much beyond infectious diseases and into oncology. The review
thus showcases how mRNA technology can revolutionize the field of cancer
medicine as well. Applications include therapeutic cancer vaccines, mRNA
encoding for immune-modulatory agents such as cytokines and monoclonal
antibodies, and the modification of immune cells, such as CAR-T cells.
Since mRNA can mount targeted and very powerful immune responses and
also has a form of adaptability for personalized medicine, it truly presents
mRNA as a suitable tool against a vast range of malignancies. The review
further explores new delivery technologies, clinical evaluations, real-world
applications, and the current hurdles of stability, delivery, and tumor
heterogeneity. With more and more therapeutic mRNA advancing rapidly,
oncology is witnessing the coming of a new wave that centers around
precision, efficacy, and least system toxicity. Explore further and
emphasizes the need for continued investigation and collaboration to harness
the mRNA therapeutic potential in cancer therapeutics fully.

Files

20 WJAPS 199.pdf

Files (546.6 kB)

Name Size Download all
md5:4c6357d537c42b4f7610b63799f1f052
546.6 kB Preview Download

Additional details

Identifiers

ISSN
3049-3013

Related works

Is referenced by
Journal article: 3049-3013 (ISSN)

References

  • Gote V, Bolla PK, Kommineni N, Butreddy A, Nukala PK, Palakurthi SS, Khan W. A Comprehensive Review of mRNA Vaccines. Int J Mol Sci., 2023 Jan 31; 24(3): 2700.
  • Khurana A, Allawadhi P, Khurana I, Allwadhi S, Weiskirchen R, Banothu AK, Chhabra D, Joshi K, Bharani KK. Role of nanotechnology behind the success of mRNA vaccines for COVID-19. Nano Today, 2021 Jun; 38: 101142.
  • Li Q, Lei X, Zhu J, Zhong Y, Yang J, Wang J, Tan H. Radiotherapy/Chemotherapy-Immunotherapy for Cancer Management: From Mechanisms to Clinical Implications. Oxid Med Cell Longev, 2023 Feb 2; 2023: 7530794.
  • Liu YP, Zheng CC, Huang YN, He ML, Xu WW, Li B. Molecular mechanisms of chemo- and radiotherapy resistance and the potential implications for cancer treatment. MedComm (2020)., 2021 Jun 10; 2(3): 315-340.
  • Kaczmarek M, Poznańska J, Fechner F, Michalska N, Paszkowska S, Napierała A, Mackiewicz A. Cancer Vaccine Therapeutics: Limitations and Effectiveness-A Literature Review. Cells, 2023 Aug 28; 12(17): 2159.
  • Sun H, Zhang Y, Wang G, Yang W, Xu Y. mRNA-Based Therapeutics in Cancer Treatment. Pharmaceutics, 2023 Feb 13; 15(2): 622.
  • Paczkowska A, Hoffmann K, Andrzejczak A, Pucek WF, Kopciuch D, Bryl W, Nowakowska E, Kus K. The Application of mRNA Technology for Vaccine Production-Current State of Knowledge. Vaccines (Basel), 2025 Apr 4; 13(4): 389.
  • Zhang G, Tang T, Chen Y, Huang X, Liang T. mRNA vaccines in disease prevention and treatment. Signal Transduct Target Ther., 2023 Sep 20; 8(1): 365.
  • Wang YS, Kumari M, Chen GH, Hong MH, Yuan JP, Tsai JL, Wu HC. mRNA-based vaccines and therapeutics: an in-depth survey of current and upcoming clinical applications. J Biomed Sci., 2023 Oct 7; 30(1): 84.
  • Rhoads RE. Synthetic mRNA: Production, Introduction into Cells, and Physiological Consequences. Methods Mol Biol., 2016; 1428: 3-27.
  • Vishweshwaraiah YL, Dokholyan NV. mRNA vaccines for cancer immunotherapy. Front Immunol, 2022 Dec 14; 13: 1029069.
  • Sahin, U., Karikó, K. & Türeci, Ö. mRNA-based therapeutics — developing a new class of drugs. Nat Rev Drug Discov, 2014; 13: 759–780.
  • Qin S, Tang X, Chen Y, Chen K, Fan N, Xiao W, Zheng Q, Li G, Teng Y, Wu M, Song X. mRNA-based therapeutics: powerful and versatile tools to combat diseases. Signal Transduct Target Ther., 2022 May 21; 7(1): 166.
  • Chaudhary N, Weissman D, Whitehead KA. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat Rev Drug Discov., 2021 Nov; 20(11): 817-838.
  • Vallet T, Vignuzzi M. Self-Amplifying RNA: Advantages and Challenges of a Versatile Platform for Vaccine Development. Viruses, 2025 Apr 14; 17(4): 566.
  • Shafaghat Z, Radmehr S, Saharkhiz S, Khosrozadeh A, Feiz K, Alkhathami AG, Taheripak G, Ramezani Farani M, Rahmati R, Zarimeidani F, Bassereh H, Bakhtiyari S, Alipourfard I. Circular RNA, A Molecule with Potential Chemistry and Applications in RNA-based Cancer Therapeutics: An Insight into Recent Advances. Top Curr Chem (Cham), 2025 May 9; 383(2): 21.
  • Perkovic M, Gawletta S, Hempel T, Brill S, Nett E, Sahin U, Beissert T. A trans-amplifying RNA simplified to essential elements is highly replicative and robustly immunogenic in mice. Mol Ther., 2023 Jun 7; 31(6): 1636-1646.
  • Son S, Lee K. Development of mRNA Vaccines/Therapeutics and Their Delivery System. Mol Cells, 2023 Jan 31; 46(1): 41-47.
  • Hınçer A, Ahan RE, Aras E, Şeker UÖŞ. Making the Next Generation of Therapeutics: mRNA Meets Synthetic Biology. ACS Synth Biol., 2023 Sep 15; 12(9): 2505-2515.
  • Wang Y, Zhang Z, Luo J, Han X, Wei Y, Wei X. mRNA vaccine: a potential therapeutic strategy. Mol Cancer, 2021 Feb 16; 20(1): 33.
  • Jung HN, Lee SY, Lee S, Youn H, Im HJ. Lipid nanoparticles for delivery of RNA therapeutics: Current status and the role of in vivo imaging. Theranostics, 2022 Oct 24; 12(17): 7509-7531.
  • Alfagih IM, Aldosari B, AlQuadeib B, Almurshedi A, Alfagih MM. Nanoparticles as Adjuvants and Nanodelivery Systems for mRNA-Based Vaccines. Pharmaceutics, 2020 Dec 30; 13(1): 45.
  • Yokoo H, Oba M, Uchida S. Cell-Penetrating Peptides: Emerging Tools for mRNA Delivery. Pharmaceutics, 2021 Dec 29; 14(1): 78.
  • Chen W, Zhu Y, He J, Sun X. Path towards mRNA delivery for cancer immunotherapy from bench to bedside. Theranostics, 2024 Jan 1; 14(1): 96-115.
  • Peng M, Mo Y, Wang Y, Wu P, Zhang Y, Xiong F, Guo C, Wu X, Li Y, Li X, Li G, Xiong W, Zeng Z. Neoantigen vaccine: an emerging tumor immunotherapy. Mol Cancer, 2019 Aug 23; 18(1): 128.
  • Beck JD, Reidenbach D, Salomon N, Sahin U, Türeci Ö, Vormehr M, Kranz LM. mRNA therapeutics in cancer immunotherapy. Mol Cancer., 2021 Apr 15; 20(1): 69.
  • Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell., 2015 Apr 13; 27(4): 450-61.
  • Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov., 2015 Sep; 14(9): 642-62.
  • Kong N, Tao W, Ling X, Wang J, Xiao Y, Shi S, Ji X, Shajii A, Gan ST, Kim NY, Duda DG, Xie T, Farokhzad OC, Shi J. Synthetic mRNA nanoparticle-mediated restoration of p53 tumor suppressor sensitizes p53-deficient cancers to mTOR inhibition. Sci Transl Med., 2019 Dec 18; 11(523): eaaw1565.
  • Vélez DE, Torres BL, Hernández G. The Bright Future of mRNA as a Therapeutic Molecule. Genes (Basel)., 2025 Mar 26; 16(4): 376.
  • Chehelgerdi, M., Chehelgerdi, M. The use of RNA-based treatments in the field of cancer immunotherapy. Mol Cancer, 2023; 22: 106.
  • Zhang, G., Tang, T., Chen, Y. et al. mRNA vaccines in disease prevention and treatment. Sig Transduct Target Ther, 2023; 8: 365.
  • Wang J, Ding Y, Chong K, Cui M, Cao Z, Tang C, Tian Z, Hu Y, Zhao Y, Jiang S. Recent Advances in Lipid Nanoparticles and Their Safety Concerns for mRNA Delivery. Vaccines (Basel)., 2024 Oct 8; 12(10): 1148.
  • Weber JS, Carlino MS, Khattak A, Meniawy T, Ansstas G, Taylor MH, Kim KB, McKean M, Long GV, Sullivan RJ, Faries M, Tran TT, Cowey CL, Pecora A, Shaheen M, Segar J, Medina T, Atkinson V, Gibney GT, Luke JJ, Thomas S, Buchbinder EI, Healy JA, Huang M, Morrissey M, Feldman I, Sehgal V, Robert-Tissot C, Hou P, Zhu L, Brown M, Aanur P, Meehan RS, Zaks T. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet, 2024 Feb 17; 403(10427): 632-644.
  • Li X, You J, Hong L, Liu W, Guo P, Hao X. Neoantigen cancer vaccines: a new star on the horizon. Cancer Biol Med., 2023 Dec 29; 21(4): 274–311.
  • Wadhwa A, Aljabbari A, Lokras A, Foged C, Thakur A. Opportunities and Challenges in the Delivery of mRNA-based Vaccines. Pharmaceutics, 2020 Jan 28; 12(2): 102.
  • Youssef M, Hitti C, Puppin Chaves Fulber J, Kamen AA. Enabling mRNA Therapeutics: Current Landscape and Challenges in Manufacturing. Biomolecules, 2023 Oct 9; 13(10): 1497.
  • Li Y, Wang M, Peng X, Yang Y, Chen Q, Liu J, She Q, Tan J, Lou C, Liao Z, Li X. mRNA vaccine in cancer therapy: Current advance and future outlook. Clin Transl Med., 2023 Aug; 13(8): e1384.
  • Kumar A, Dixit S, Srinivasan K, M D, Vincent PMDR. Personalized cancer vaccine design using AI-powered technologies. Front Immunol, 2024 Nov 8; 15: 1357217.
  • Li D, Liu C, Li Y, Tenchov R, Sasso JM, Zhang D, Li D, Zou L, Wang X, Zhou Q. Messenger RNA-Based Therapeutics and Vaccines: What's beyond COVID-19? ACS Pharmacol Transl Sci., 2023 Jul 3; 6(7): 943-969.